Best practices of ASRM and ESHRE: a journey through reproductive medicine
ABSTRACT BACKGROUND: The American Society for Reproductive Medicine (ASRM) and the European Society of Human Reproduction and Embryology (ESHRE) are the two largest societies in the world whose members comprise the major experts and professionals working in the field of reproductive medicine and embryology. These societies have never before had a joint scientific meeting. METHODS: A 3-day meeting was planned and took place in March of 2012. The goal was to present and debate key topics, as well as modes of practice in reproductive medicine and to discuss recent developments in the field. RESULTS: Presentations by members of ASRM and ESHRE were of three types: 'state of the art' lectures, 'back-to-back' presentations of two points of view and debates. CONCLUSIONS: For the first time, ASRM and ESHRE held a joint meeting where a special emphasis was given to presentations on the hottest topics in the field. Although different opinions and approaches sometimes exist on the two sides of the Atlantic, an appreciation and acceptance of these differences was evident, and there was more commonality than divergence of opinion.
- SourceAvailable from: Kirstine Kirkegaard
[Show abstract] [Hide abstract]
- "Our findings support the hypothesis that gene expression profiles correlate with outcome and present a tentative list of the differentially expressed genes. Elective transfer of a single embryo (SET) is increasingly recommended as best practice in IVF treatment (Maheshwari et al., 2011; Gianaroli et al., 2012), which requires a reliable assessment of embryo quality. Embryo selection is currently based on morphology (2011), and although morphology is correlated fairly closely with the reproductive potential, the inability reliably to predict embryo viability is often considered a main reason for the relatively low pregnancy rate following assisted reproduction treatment. "
ABSTRACT: Results from animal models points towards the existence of a gene expression profile that is distinguishably different in viable embryos compared with non-viable embryos. Knowledge of human embryo transcripts is however limited, in particular with regard to how gene expression is related to clinical outcome. The purpose of the present study was therefore to determine the global gene expression profiles of human blastocysts. Next Generation Sequencing was used to identify genes that were differentially expressed in non-implanted embryos and embryos resulting in live birth. Three trophectoderm biopsies were obtained from morphologically high quality blastocysts resulting in live birth and three biopsies were obtained from non-implanting blastocysts of a comparable morphology. Total RNA was extracted from all samples followed by complete transcriptome sequencing. Using a set of filtering criteria, we obtained a list of 181 genes that were differentially expressed between trophectoderm biopsies from embryos resulting in either live birth or no implantation (negative hCG), respectively. We found that 37 of the 181 genes displayed significantly differential expression (p<0.05), e.g. EFNB1, CYTL1 and TEX26 and TESK1, MSL1 and EVI5 in trophectoderm biopsies associated with live birth and non-implanting, respectively. Out of the 181 genes, almost 80% (145 genes) were up-regulated in biopsies from un-implanted embryos, whereas only 20% (36 genes) showed an up-regulation in the samples from embryos resulting in live birth. Our findings suggest the presence of molecular differences visually undetectable between implanted and non-implanted embryos, and represent a proof of principle study. Copyright © 2015. Published by Elsevier B.V.Gene 06/2015; DOI:10.1016/j.gene.2015.06.057 · 2.08 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: The aim of this study was to examine the effect of clomiphene citrate [CC] co-administration during the use of exogenous low-dose urinary FSH [uFSH] for induction of ovulation in CC-resistant infertile PCOS women. In a randomised controlled setting, 174 CC-resistant infertile PCOS women were randomized into two parallel groups; Group I received CC 100 mg/day for 5 days plus uFSH 37.5 IU/day while group II received only uFSH 37.5 IU /day. Subsequent increments of uFSH by 37.5 IU/day were made according to response. Primary outcome was ovulation rate. Secondary outcomes were clinical pregnancy rates, number of follicles, endometrial thickness, and gonadotropins consumption. Our results have demonstrated that group I compared to group II had significantly higher ovulation rate per intention to treat [ITT] [72.4 % vs. 34.2 %, p < 0.001]. Clinical pregnancy and live birth rates were comparable between the two groups. Group I consumed significantly lower total FSH dose and needed significantly shorter stimulation duration compared to group II. CC co-administered during low dose HP uFSH versus uFSH for CC-resistant PCOS yields significantly higher ovulation rate and less consumption of FSH.Journal of Assisted Reproduction and Genetics 09/2013; 30(11). DOI:10.1007/s10815-013-0090-2 · 1.77 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Nanomaterial-mediated delivery represents a promising technique for reproductive biology with a potential to improve the safety and efficacy of existing methodologies, including experimental gene therapy and sperm-mediated gene transfer. Mesoporous silica nanoparticles (MSNPs) have been characterised as a powerful and safe delivery tool, rendering them an excellent candidate for use in reproductive research. However, their effects upon mammalian gametes with highly specialised structure and functionality remain untested. Here, we show for the first time, that spherical MSNPs with hexagonal pore symmetry, functionalised with polyethileneimine and aminopropyltriethoxysilane, and optionally loaded with two common types of cargo (nucleic acid/protein), form strong associations with boar sperm following incubation in vitro and do not exert negative effect upon the main parameters of sperm function, including motility, viability, acrosomal status and DNA fragmentation index. Our findings provide a rationale for the use of MSNPs for the transfer of investigative, diagnostic and/or therapeutic compounds into mammalian sperm.Nanomedicine: nanotechnology, biology, and medicine 11/2013; 10(4):859-70. DOI:10.1016/j.nano.2013.10.011 · 5.98 Impact Factor